SIM-0709

N/A

Report date: 2026/04/03 20:03:44

Base Information

Drug NameSIM-0709
Drug Alias NameSIM-0709SIM0709
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionInterleukin-23 subunit p19 inhibitorsTumor necrosis factor superfamily member 15 inhibitors
TargetsInterleukin-23 subunit p19Tumor necrosis factor superfamily member 15
Therapy Area/IndicationsInflammatory Bowel Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesSimcere Pharmaceutical Group Ltd
China Registration ClassN/A

Develop Information

Active CompaniesC.H. Boehringer Sohn Ag & Co. KgSimcere Pharmaceutical Group Ltd
Inactive CompaniesN/A
Active IndicationsInflammatory Bowel Diseases
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A